From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
ADSB-FUB-187 structure.png
Legal status
Legal status
CAS Number
PubChem CID
Chemical and physical data
Molar mass564.07 g·mol−1
3D model (JSmol)

ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM. It was originally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.[1]


Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.[2]

See also[edit]


  1. ^ "Patent WO/2009/106982 - Indazole derivatives". Cite journal requires |journal= (help)
  2. ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. Retrieved 8 July 2015.